This week, the International Generic and Biosimilar Medicines Association (IGBA) was elected as a Management Committee Member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
This week, the International Generic and Biosimilar Medicines Association (IGBA) was elected as a Management Committee Member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
The ICH works to achieve “greater harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed and registered in the most resource-efficient manner,” according to their mission statement.
The Management Committee of the ICH is a distinguished group of ICH members that help to oversee the operational aspects of ICH on behalf of all members, including administrative and financial matters, in addition to the oversight of working groups.
IGBA joined the ICH in June 2016 as a General Assembly member. With its newly elected role, the IGBA will be represented at Management Committee meetings by 2 current IGBA representatives.
“To join the ICH as Management Committee’s Member is a historical moment for our industry and next milestone for the generic and biosimilar industries’ engagement in the international harmonization process,” said Nick Cappuccino, chair of the IGBA science committee and one of IGBA’s representatives to the ICH General Assembly, in a statement.
The IGBA believes that, by being more deeply involved with the ICH Management Body, it can drive deeper integration of ICH regulatory standards among its own membership. This working partnership will in turn, it says, benefit patients worldwide and provide them with access to high quality, safe, and effective generic and biosimilar medicines.
“The positive decision of the ICH to elect the IGBA as a Management Committee Member reflects the recognition of values and expertise which the generic and biosimilar pharmaceutical industries can bring to the scientific discussion at the ICH,” said Beata Stepniewska, the second IGBA representative to the ICH General Assembly.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.